SCHEMBL2369758

SCHEMBL2369758

CSc1nc(Cl)cc(-c2cc(F)ccc2SC)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
ALDH1A1 P00352 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
GAA P10253 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
POLB P06746 1/20 0.35
HSP90AB1 P08238 3/20 0.34
HTT P42858 1/20 0.33
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
ADRA1D P25100 1/20 0.33
ADRA1A P35348 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2370289 0.88 ALOX5AP (0.39) ALOX5APFEN1ALDH1A1L3MBTL1KMT2A
SCHEMBL21263117 0.73 ATR (0.41) KMT2AMEN1GAASMN1; SMN2LMNA
SCHEMBL2369993 0.69 ATR (0.46)
SCHEMBL62021 0.69 POLB (0.53) KMT2AMEN1GAASMN1; SMN2LMNA
SCHEMBL7521036 0.68 KDM4E (0.56) ALDH1A1L3MBTL1KMT2AMEN1GAA
SCHEMBL19805989 0.68 POLB (0.46) ALDH1A1L3MBTL1KMT2AMEN1GAA
SCHEMBL25233668 0.68 PLA2G7 (0.43) ALDH1A1KMT2AMEN1GAASMN1; SMN2
SCHEMBL30405651 0.68 PLA2G7 (0.43) ALDH1A1KMT2AMEN1GAASMN1; SMN2
SCHEMBL16540834 0.67 MAP3K14 (0.39) ALDH1A1L3MBTL1KMT2AMEN1GAA
Ammonia Solution, Strong SCHEMBL15015765 0.67 KMT2A (0.43) KMT2AMEN1GAASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9249129-B2 Morpholino substituted urea derivatives as mTOR inhibitors CELLZOME LIMITED (GB) 2016-02-02 US disclosed
EP-2542536-B1 Morpholino substituted urea derivatives as mtor inhibitors CELLZOME LTD (GB) 2015-01-21 EP disclosed
US-20130196982-A1 MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS CELLZOME LIMITED (GB) 2013-08-01 US disclosed
EP-2542536-A1 MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS Cellzome Limited (GB) 2013-01-09 EP disclosed
WO-2011107585-A1 MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS CELLZOME LIMITED (GB) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196982-A1 MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS MTOR, EIF4E, EIF4A1 ALOX5AP 3959/4885FEN1 2490/4885ALDH1A1 4298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.